περισσότερες πληροφορίες για το προιον
οι τυποι συμμετείχαν στο συνέδριο στη σκωτια και συμφωνα με ερευνα τους μαζι με χρηση φιναστεριδης 1mg το CG 210 αυξανει τη διαμετρο της τριχας κατα περιπου 40%
P058
A randomized, double-blind, and placebo-controlled 12-month efficacy study of
CG 210 on hair diameter in male alopecia subjects already using Finasteride 1mg
A Takeda1, S Harti2, J Liu2, L Zhang3 and A Sato4 1School of Medicine, Kitasato University,
Kanagawa, Japan; 2Legacy Healthcare, Lausanne, Switzerland; 3Legacy Healthcare, Lausanne,
Switzerland and 4Tokyo Memorial Clinic, Tokyo, Japan
Study rationale: Finesteride is often regarded as first-line treatment for male patients with androgenic
alopecia (AGA). However, after several years of treatment, patients often reach a plateau.
CG210 is a GMP-grade topical botanical blend that has clinically demonstrated its efficacy to
reestablish regular A/T ratio (and hence normal hair cycle) in AGA sufferers within 44 days. Its
unique clinically validated mechanisms of action are: preventing premature apoptosis of cells in
hair follicles; reducing micro-inflammation in the scalp, and increasing collagen content. We
would expect to get a beneficial effect when combining oral Finasteride 1mg (acting on
androgens) with topical CG210 (acting on apoptosis and micro-inflammation, two key factors
causing hair loss).
Hair diameter is an accurate clinical parameter for hair miniaturization (larger diameter¼longer
anagen phase¼improved proportion of anagen vs telogen hair (A/T ratio)). An increase in hair
diameter should also affect the cosmetic appearance and hair volume.
Objective: To evaluate the clinical effect of the topical anti-hair loss CG210 vs placebo on hair
diameter in Japanese AGA patients already using Finasteride 1mg for 43 years.
Study design: Randomized, double-blind, placebo-controlled, single-center, prospective, with
two parallel groups.
Group A: Topical placebo provided to nine male alopecia subjects already taking Finasteride
1mg treatment for 43 years.
Group B: Topical CG210 provided to seven male alopecia subjects already taking Finasteride
1mg treatment for 43 years.
Results: Mean diameter of hair in the Finesterideþtopical CG210 group versus Finesterideþplacebo
group increased by 36.9%. No adverse events were observed.
Conclusion: Application of topical CG210 in combination with Finasteride 1mg demonstrated a
statistically and clinically significant improvement in hair diameter and overall cosmetic appearance.
Therefore, CG210 offers AGA sufferers an effective option to be used either alone to preve
http://www.cg210.com/
http://www.cg210.com/library/pdf/PR_Legacy_WCHR_120213.pdf
ξερεις φιλε μου ενδεικτικα να μας πεις τιμη ?